Akebia Therapeutics, Inc.

NasdaqCM:AKBA 주식 보고서

시가총액: US$198.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Akebia Therapeutics 관리

관리 기준 확인 2/4

Akebia Therapeutics' CEO는 John Butler, Sep2013 에 임명되었습니다 의 임기는 10.75 년입니다. 총 연간 보상은 $ 2.78M, 28.7% 로 구성됩니다. 28.7% 급여 및 71.3% 보너스(회사 주식 및 옵션 포함). 는 $ 1.48M 가치에 해당하는 회사 주식의 0.7% 직접 소유합니다. 1.48M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 5.5 년입니다.

주요 정보

John Butler

최고 경영자

US$2.8m

총 보상

CEO 급여 비율28.7%
CEO 임기10.8yrs
CEO 소유권0.7%
경영진 평균 재임 기간1.5yrs
이사회 평균 재임 기간5.6yrs

최근 관리 업데이트

Recent updates

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23
Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Oct 07

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10
Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Jun 30

Another Look At Akebia Therapeutics

Sep 06

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?

Jun 24
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?

Akebia wins $40M Department of Veterans Affairs contract

Jun 15

FDA accepts Akebia's vadadustat NDA for review

Jun 01

Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?

May 26
Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?

CEO 보상 분석

John Butler 의 보수는 Akebia Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$43m

Dec 31 2023US$3mUS$796k

-US$52m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$3mUS$765k

-US$94m

Sep 30 2022n/an/a

-US$158m

Jun 30 2022n/an/a

-US$163m

Mar 31 2022n/an/a

-US$276m

Dec 31 2021US$3mUS$718k

-US$282m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$300m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$6mUS$696k

-US$385m

Sep 30 2020n/an/a

-US$391m

Jun 30 2020n/an/a

-US$386m

Mar 31 2020n/an/a

-US$268m

Dec 31 2019US$4mUS$648k

-US$280m

Sep 30 2019n/an/a

-US$245m

Jun 30 2019n/an/a

-US$217m

Mar 31 2019n/an/a

-US$193m

Dec 31 2018US$3mUS$595k

-US$144m

Sep 30 2018n/an/a

-US$68m

Jun 30 2018n/an/a

-US$65m

Mar 31 2018n/an/a

-US$53m

Dec 31 2017US$3mUS$543k

-US$74m

보상 대 시장: John 의 총 보상 ($USD 2.78M )은 US 시장( $USD 1.62M ).

보상과 수익: John 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

John Butler (60 yo)

10.8yrs

테뉴어

US$2,775,123

보상

Mr. John P. Butler, MBA, serves as Non-Executive Director at Wren Therapeutics Limited since 2023. He has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013 an...

리더십 팀

이름위치테뉴어보상소유권
John Butler
CEO, President & Director10.8yrsUS$2.78m0.70%
$ 1.4m
Michel Dahan
Senior VP & COOno dataUS$1.25m0.32%
$ 636.1k
Steven Burke
Senior VP of Research & Development and Chief Medical Officer4.9yrsUS$1.21m0.16%
$ 324.5k
Erik Ostrowski
Chief Financial Officerless than a year데이터 없음데이터 없음
Richard Malabre
Chief Accounting Officerless than a year데이터 없음데이터 없음
Kimberly Garko
Senior VP & Chief Technical Officerless than a year데이터 없음데이터 없음
Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration1.5yrs데이터 없음데이터 없음
Mercedes Carrasco
Senior Director of Investor & Corporate Communicationsno data데이터 없음데이터 없음
Meredith Bowman
Senior VP & Chief People Officer2.5yrs데이터 없음데이터 없음
Carolyn Rucci
Senior VP of Legal & General Counsel2.5yrs데이터 없음데이터 없음
Nicholas Grund
Senior VP & Chief Commercial Officerless than a year데이터 없음데이터 없음

1.5yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: AKBA 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
John Butler
CEO, President & Director11yrsUS$2.78m0.70%
$ 1.4m
Michael Rogers
Independent Director5.6yrsUS$145.79k0.046%
$ 90.9k
Adrian Adams
Independent Chairperson5.6yrsUS$171.63k0.064%
$ 127.6k
LeAnne Zumwalt
Independent Director3.4yrsUS$143.31k0.021%
$ 41.4k
Ronald Frieson
Independent Director2.7yrsUS$147.97k0.021%
$ 41.4k
Steven Gilman
Independent Director5.6yrsUS$139.87k0.042%
$ 82.5k
Cynthia Smith
Independent Director5.9yrsUS$151.50k0.045%
$ 90.1k
Myles Wolf
Independent Director4.3yrsUS$144.43k0.032%
$ 64.1k

5.6yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: AKBA 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.